Aurobindo Pharma may move to Rs 820, says Rajat Bose

Rajat Bose of rajatkbose.com told CNBC-TV18, "In the recent past the pharma shares came down for a lot of hammering because of USFDA and many other issues but now only recently we have seen that lots of good news from the same site coming in and Aurobindo Pharma is also showing a good sign of recovery, so I would suggest a stoploss of Rs 650 and I would say that don’t buy it for three months or four months."

"If you get good profits that is separate, otherwise for calendar year 2017 my target is about Rs 820. It is a good pharma company and is likely to earn some good money here as well," he added.